The MMRC brings together an extraordinary assembly of distinguished myeloma researchers and world-renowned academic institutions to speed translational and clinical developments in myeloma.

MMRC Member Institutions include:

• Dana-Farber Cancer Institute*
  Boston, Mass.
• H. Lee Moffitt Cancer Center & Research Institute*
  Tampa, Fla.
• Mayo Clinic Cancer Center*
  Rochester, Minn.
  Phoenix/Scottsdale, Ariz.
  Jacksonville, Fla.
• City of Hope National Medical Center
  Duarte, Calif.
• Emory University
  Atlanta, Ga.
• Hackensack University Medical Center
  Hackensack, N.J.
• Ohio State University Comprehensive Cancer Center
  Columbus, OH
• Roswell Park Cancer Institute
  Buffalo, N.Y.
• Saint Vincent Catholic Medical Centers of New York
  New York, N.Y.
• University Health Network (Princess Margaret Hospital)
  Toronto, Ontario, CANADA
• University of Chicago
  Chicago, Ill.
• University of Michigan, Ann Arbor
  Ann Arbor, MI.
• Washington University in St. Louis
  St. Louis, Mo.

* These academic centers are also Founding Institutions and are represented on the MMRC Steering Committee.

The MMRC's outstanding Member Institutions, responsible for initiating MMRC research and drug development projects, were identified by the MMRC as the foremost myeloma research centers based on the following criteria:

• Large number of National Institutes of Health (NIH) peer-reviewed grant awards, including all Founding Institutions having received P01 funding
• Large number of peer-reviewed publications
• Extraordinary scientific endeavors
• World-renowned clinical expertise
• Large number of myeloma patients and physician referrals
• Collaborative approach to science

MMRC Member Institutions are now conducting innovative research efforts in the most promising areas of myeloma. Together, MMRC Institutions' efforts will yield important discoveries, resulting in unprecedented scientific advances well beyond the scope of any one research institution.